雷珠单抗联合氪激光治疗视网膜分支静脉阻塞继发黄斑水肿的观察  

Ranibizumab combined with grid laser photocoagulation for treating macular edema secondary to branch retinal vein occlusion

作　　者：郭凯[1] 胡昕倩[2] 王春燕[1] 杨大勇[1] 朱丹[1] 

机构地区：[1]内蒙古医科大学附属医院,呼和浩特010059 [2]中山大学中山眼科中心,广州

出　　处：《中华眼外伤职业眼病杂志》2014年第5期344-346,共3页Chinese Journal of Ocular Trauma and Occupational Eye Disease

摘　　要：目的 探讨雷珠单抗（Ranibizumab）联合氪激光治疗视网膜分支静脉阻塞（branch retinal vein occlusion,BRVO）继发黄斑水肿的效果.方法 10例（10只眼）BRVO继发黄斑水肿患者接受雷珠单抗玻璃体注射及氪激光局部视网膜光凝,2周、4周后随访,对比治疗前后的最佳矫正视力及黄斑中心凹厚度.结果 治疗前最佳矫正视力为0.25 ±0.12,平均黄斑中心凹厚度为（465±123） μm,治疗后2周、4周最佳矫正视力分别为0.32 ±0.16（P =0.031）,0.46 ±0.13（P =0.031）;2周、4周平均黄斑中心凹厚度为（325 ±89） μm（P =0.040）,（285 ±50） μm（P =0.008）.结论 雷珠单抗联合氪激光治疗视网膜分支静脉阻塞继发黄斑水肿,可以显著提高视力,促进黄斑水肿吸收.Objective To evaluate intravitreal Ranibizumab combined with grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion （ BRVO ）. Methods Ten eyes of 10 patients with macular edema associated with BR^O were included. Intravitreal bevacizumab was administered and then laser photocoagulation was performed 10 days later. The follow up was 2 weeks and 4 weeks. The best-corrected visual acuity （BCVA） and central macular thickness were measured after treatment and compared with baseline BCVA and central macular thickness. Results The mean baseline BCVA was 0.25 ±0.12, and the mean central macular thickness was （465 ± 123） μm. The mean BCVAs at 2 and 4 weeks after treatment were 0.32 ±0. 16 （ P = O. 031 ） and 0.46 ± 0.13 （ P = 0.031 ） respectively, The mean central macular thickness at 2 and 4 weeks after treatment were （325 ± 89） μm（ P = 0. 040） and （285 ± 50 ） μm （ P = 0. 008 ）. Conclusion Intravitreal Ranibizumab combined with grid laser photocoagulation can improve BCVA and alleviate macular edema.

关 键 词：雷珠单抗 光凝 激光 阻塞 静脉 分支 视网膜 水肿 黄斑 

分 类 号：R779.63[医药卫生—眼科]